CN101267843A - 人造血小板 - Google Patents

人造血小板 Download PDF

Info

Publication number
CN101267843A
CN101267843A CNA2006800348757A CN200680034875A CN101267843A CN 101267843 A CN101267843 A CN 101267843A CN A2006800348757 A CNA2006800348757 A CN A2006800348757A CN 200680034875 A CN200680034875 A CN 200680034875A CN 101267843 A CN101267843 A CN 101267843A
Authority
CN
China
Prior art keywords
fibrinogen
peptide
precursor
conjunction
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800348757A
Other languages
English (en)
Chinese (zh)
Inventor
A·H·古多尔
S·M·泰勒
G·F·沃克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Haemostatix Ltd
Original Assignee
Haemostatix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haemostatix Ltd filed Critical Haemostatix Ltd
Publication of CN101267843A publication Critical patent/CN101267843A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNA2006800348757A 2005-08-04 2006-08-04 人造血小板 Pending CN101267843A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0516091.6 2005-08-04
GBGB0516091.6A GB0516091D0 (en) 2005-08-04 2005-08-04 Therapeutic agent

Publications (1)

Publication Number Publication Date
CN101267843A true CN101267843A (zh) 2008-09-17

Family

ID=34984119

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800348757A Pending CN101267843A (zh) 2005-08-04 2006-08-04 人造血小板

Country Status (9)

Country Link
US (2) US20090203619A1 (https=)
EP (2) EP2335737A3 (https=)
JP (1) JP2009505964A (https=)
CN (1) CN101267843A (https=)
AU (1) AU2006274685A1 (https=)
CA (1) CA2625917A1 (https=)
GB (2) GB0516091D0 (https=)
IL (1) IL189105A0 (https=)
WO (1) WO2007015107A2 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105916524A (zh) * 2014-01-08 2016-08-31 哈莫斯塔蒂斯有限公司 包含纤维蛋白原结合肽的肽类树状聚合物
CN107686506A (zh) * 2016-08-05 2018-02-13 首都医科大学 华法林‑4‑o‑乙酰‑gprp, 其合成, 活性和应用
CN104114198B (zh) * 2012-02-01 2018-09-04 哈莫斯塔蒂斯有限公司 止血伤口敷料
CN108976284A (zh) * 2017-05-31 2018-12-11 首都医科大学 含Gly-Pro-Arg-Pro的五肽修饰的华法林,其合成,活性和应用
CN108976285A (zh) * 2017-05-31 2018-12-11 首都医科大学 Gly-Pro-Arg-Pro-AA修饰的华法林,其合成,活性和应用
CN112105377A (zh) * 2018-04-24 2020-12-18 菲布赖恩特公司 血纤维蛋白原γ初始变体的治疗性用途
CN115010784A (zh) * 2022-05-16 2022-09-06 江南大学 一种ace抑制肽及其应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0623607D0 (en) * 2006-11-27 2007-01-03 Haemostatix Ltd Tissue adhesive
EP2120989A1 (en) * 2007-03-21 2009-11-25 DSM IP Assets B.V. Cholesterol lowering protein hydrolysates
WO2009046845A2 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of a lactoferrin partial peptide peptide as a therapeutic agent
KR20100057642A (ko) * 2007-09-11 2010-05-31 몬도바이오테크 래보래토리즈 아게 치료제로서의 ｃｎｐ-２２ 단독 또는 피살라에민과 배합된 이의 용도
GB201101740D0 (en) 2011-02-01 2011-03-16 Haemostatix Ltd Therapeutic agents with improved fibrinogen binding
WO2013021353A1 (en) * 2011-08-11 2013-02-14 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
WO2014197816A1 (en) * 2013-06-06 2014-12-11 Massachusetts Institute Of Technology Stimulus responsive nanocomplexes and methods of use thereof
SG10201710616XA (en) * 2013-06-28 2018-02-27 Biogen Ma Inc Thrombin cleavable linker with xten and its uses thereof
WO2015073418A2 (en) * 2013-11-15 2015-05-21 President And Fellows Of Harvard College Methods and assays for factor viii activity
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
GB201508024D0 (en) * 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107628D0 (en) 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
ATE329624T1 (de) * 1992-05-21 2006-07-15 Diatide Inc Technetium-99m markierte peptide zur bilderzeugung von thrombus
US6184205B1 (en) * 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
DE69526665T2 (de) * 1994-09-21 2002-11-21 Cytogen Corp., Princeton Antigen bindende peptide (abtides) aus peptidbibliotheken
ES2232862T3 (es) * 1996-10-21 2005-06-01 Quadrant Drug Delivery Limited Sustitutos de plaquetas y procedimientos de conjugacion apropiados para su preparacion.
WO1998055105A1 (en) * 1997-06-05 1998-12-10 Hemosphere, Inc. Fibrinogen-coated microspheres
DK9700423U3 (da) * 1997-11-10 1999-03-12 Simatek A S Multifunktion cip-dyse
WO1999042146A1 (en) * 1998-02-20 1999-08-26 Quadrant Healthcare (Uk) Limited Products comprising fibrinogen for use in therapy
GB9827813D0 (en) * 1998-12-17 1999-02-10 Andaris Ltd Pharmaceutical conjugates
US6984373B2 (en) * 2000-12-23 2006-01-10 Dyax Corp. Fibrin binding moieties useful as imaging agents
GB0323378D0 (en) * 2003-10-07 2003-11-05 Univ Leicester Therapeutic agent
GB0413346D0 (en) * 2004-06-15 2004-07-21 Theryte Ltd Treating cancer
GB201201751D0 (en) * 2012-02-01 2012-03-14 Haemostatix Ltd Haemostatic wound dressing

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104114198B (zh) * 2012-02-01 2018-09-04 哈莫斯塔蒂斯有限公司 止血伤口敷料
CN105916524A (zh) * 2014-01-08 2016-08-31 哈莫斯塔蒂斯有限公司 包含纤维蛋白原结合肽的肽类树状聚合物
CN105916524B (zh) * 2014-01-08 2021-07-20 哈莫斯塔蒂斯有限公司 包含纤维蛋白原结合肽的肽类树状聚合物
CN107686506A (zh) * 2016-08-05 2018-02-13 首都医科大学 华法林‑4‑o‑乙酰‑gprp, 其合成, 活性和应用
CN108976284A (zh) * 2017-05-31 2018-12-11 首都医科大学 含Gly-Pro-Arg-Pro的五肽修饰的华法林,其合成,活性和应用
CN108976285A (zh) * 2017-05-31 2018-12-11 首都医科大学 Gly-Pro-Arg-Pro-AA修饰的华法林,其合成,活性和应用
CN108976285B (zh) * 2017-05-31 2021-11-30 首都医科大学 Gly-Pro-Arg-Pro-AA修饰的华法林,其合成,活性和应用
CN108976284B (zh) * 2017-05-31 2021-11-30 首都医科大学 含Gly-Pro-Arg-Pro的五肽修饰的华法林,其合成,活性和应用
CN112105377A (zh) * 2018-04-24 2020-12-18 菲布赖恩特公司 血纤维蛋白原γ初始变体的治疗性用途
CN115010784A (zh) * 2022-05-16 2022-09-06 江南大学 一种ace抑制肽及其应用

Also Published As

Publication number Publication date
EP1919508B1 (en) 2015-02-25
EP1919508A2 (en) 2008-05-14
EP2335737A2 (en) 2011-06-22
IL189105A0 (en) 2008-08-07
US20090203619A1 (en) 2009-08-13
JP2009505964A (ja) 2009-02-12
GB0615545D0 (en) 2006-09-13
AU2006274685A1 (en) 2007-02-08
WO2007015107A2 (en) 2007-02-08
WO2007015107A3 (en) 2007-07-26
GB2429153C (en) 2019-01-23
GB2429153A (en) 2007-02-21
US20130029913A1 (en) 2013-01-31
CA2625917A1 (en) 2007-02-08
EP2335737A3 (en) 2013-09-25
GB0516091D0 (en) 2005-09-14
GB2429153B (en) 2010-03-10

Similar Documents

Publication Publication Date Title
US20130029913A1 (en) Artificial platelets
EP1677829B1 (en) Fibrinogen targetting microparticles for promoting haemostasis
RU2503464C2 (ru) Биогель
Srinivasan et al. In vitro and in vivo platelet targeting by cyclic RGD‐modified liposomes
JP2007507480A5 (https=)
Chan et al. Synthetic strategies for engineering intravenous hemostats
EP2005944A1 (en) Vascular occlusion solid-phase agent with immobilised platelet binding agent
US9724379B2 (en) Therapeutic agents with improved fibrinogen binding
Takeoka et al. Function of fibrinogen γ-chain dodecapeptide-conjugated latex beads under flow
US20080241233A1 (en) Targeted delivery and expression of procoagulant hemostatic activity
RU2709738C1 (ru) Композиции для инъекций на основе коллагена, способные контролировать кровотечение и/или замещать тромбоциты при геморрагических синдромах
WO2000035487A1 (en) Pharmaceutical conjugates comprising two active agents
Modery-Pawlowski Platelet-inspired Approaches in Vascular Nanomedicine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080917